The endocannabinoid system and multiple sclerosis
- PMID: 18781983
- DOI: 10.2174/138161208785740036
The endocannabinoid system and multiple sclerosis
Abstract
Multiple sclerosis (MS) is a neurodegenerative disease that is characterised by repeated inflammatory/demyelinating events within the central nervous system (CNS). In addition to relapsing-remitting neurological insults, leading to loss of function, patients are often left with residual, troublesome symptoms such as spasticity and pain. These greatly diminish "quality of life" and have prompted some patients to self-medicate with and perceive benefit from cannabis. Recent advances in cannabinoid biology are beginning to support these anecdotal observations, notably the demonstration that spasticity is tonically regulated by the endogenous cannabinoid system. Recent clinical trials may indeed suggest that cannabis has some potential to relieve, pain, spasms and spasticity in MS. However, because the CB(1) cannabinoid receptor mediates both the positive and adverse effects of cannabis, therapy will invariably be associated with some unwanted, psychoactive effects. In an experimental model of MS, and in MS tissue, there are local perturbations of the endocannabinoid system in lesional areas. Stimulation of endocannabinoid activity in these areas either through increase of synthesis or inhibition of endocannabinoid degradation offers the positive therapeutic potential of the cannabinoid system whilst limiting adverse events by locally targeting the lesion. In addition, CB(1) and CB(2) cannabinoid receptor stimulation may also have anti-inflammatory and neuroprotective potential as the endocannabinoid system controls the level of neurodegeneration that occurs as a result of the inflammatory insults. Therefore cannabinoids may not only offer symptom control but may also slow the neurodegenerative disease progression that ultimately leads to the accumulation of disability.
Similar articles
-
Role of cannabinoids in multiple sclerosis.CNS Drugs. 2011 Mar;25(3):187-201. doi: 10.2165/11539000-000000000-00000. CNS Drugs. 2011. PMID: 21323391 Review.
-
Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis.Handb Exp Pharmacol. 2015;231:213-31. doi: 10.1007/978-3-319-20825-1_7. Handb Exp Pharmacol. 2015. PMID: 26408162 Review.
-
The endocannabinoid system in amyotrophic lateral sclerosis.Curr Pharm Des. 2008;14(23):2306-16. doi: 10.2174/138161208785740081. Curr Pharm Des. 2008. PMID: 18781981 Review.
-
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.Neurobiol Dis. 2005 Nov;20(2):207-17. doi: 10.1016/j.nbd.2005.03.002. Neurobiol Dis. 2005. PMID: 16242629
-
[News about therapeutic use of Cannabis and endocannabinoid system].Med Clin (Barc). 2004 Mar 20;122(10):390-8. doi: 10.1016/s0025-7753(04)74251-7. Med Clin (Barc). 2004. PMID: 15033046 Review. Spanish.
Cited by
-
Medicinal herbs and multiple sclerosis: Overview on the hard balance between new therapeutic strategy and occupational health risk.Front Cell Neurosci. 2022 Nov 10;16:985943. doi: 10.3389/fncel.2022.985943. eCollection 2022. Front Cell Neurosci. 2022. PMID: 36439198 Free PMC article. Review.
-
Physical exercise and synaptic protection in human and pre-clinical models of multiple sclerosis.Neural Regen Res. 2024 Aug 1;19(8):1768-1771. doi: 10.4103/1673-5374.389359. Epub 2023 Nov 8. Neural Regen Res. 2024. PMID: 38103243 Free PMC article.
-
Role of cannabinoids in multiple sclerosis.CNS Drugs. 2011 Mar;25(3):187-201. doi: 10.2165/11539000-000000000-00000. CNS Drugs. 2011. PMID: 21323391 Review.
-
Presence and regulation of cannabinoid receptors in human retinal pigment epithelial cells.Mol Vis. 2009 Jun 14;15:1243-51. Mol Vis. 2009. PMID: 19547718 Free PMC article.
-
New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids.Ther Clin Risk Manag. 2010 Mar 3;6:59-63. doi: 10.2147/tcrm.s5974. Ther Clin Risk Manag. 2010. PMID: 20234785 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical